N Akuta

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. pmc Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Clin Microbiol 51:2862-8. 2013
  2. doi request reprint Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 85:1028-36. 2013
  3. doi request reprint Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 56:37-45. 2013
  4. doi request reprint Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:417-25. 2012
  5. doi request reprint Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatology 56:2134-41. 2012
  6. doi request reprint Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 84:1593-9. 2012
  7. doi request reprint Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 84:1097-105. 2012
  8. doi request reprint Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:231-41. 2012
  9. doi request reprint Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1032-9. 2009
  10. ncbi request reprint Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007

Detail Information

Publications101 found, 100 shown here

  1. pmc Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Clin Microbiol 51:2862-8. 2013
    ....
  2. doi request reprint Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 85:1028-36. 2013
    ..It is concluded that it is difficult to predict at baseline the emergence of telaprevir-resistant variants after commencement of triple therapy in prior non-responders of HCV genotype 1, even with the use of ultra-deep sequencing...
  3. doi request reprint Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 56:37-45. 2013
    ..Anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus (HCV)-related compensated cirrhosis is still unclear...
  4. doi request reprint Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:417-25. 2012
    ....
  5. doi request reprint Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatology 56:2134-41. 2012
    ..In patients of Arg70 at the initial visit, the cumulative change rates from Arg70 to Gln70(His70) in IL28B rs8099917 non-TT genotype were significantly higher than those in the TT genotype...
  6. doi request reprint Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 84:1593-9. 2012
    ..In conclusion, the present results suggest that IL28B genotype might partly affect viral response of HCV genotype 2 to combination therapy...
  7. doi request reprint Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 84:1097-105. 2012
    ....
  8. doi request reprint Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:231-41. 2012
    ..To evaluate predictive factors of treatment efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b)...
  9. doi request reprint Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1032-9. 2009
    ....
  10. ncbi request reprint Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007
    ..In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal...
  11. doi request reprint Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:385-93. 2008
    ..The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear...
  12. ncbi request reprint Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005
    ..Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment virological features of NVRs...
  13. ncbi request reprint Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
    ..This study identified predictors of efficacy of PEG-IFN-RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b...
  14. doi request reprint A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
    ..Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV...
  15. ncbi request reprint Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:550-8. 2005
    ..Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis...
  16. ncbi request reprint Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 40:688-96. 2005
    ..The long-term effects of multi-course interferon (IFN) monotherapy in patients infected with hepatitis C virus (HCV) are still unclear...
  17. ncbi request reprint Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
    ..To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response...
  18. ncbi request reprint Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 46:403-10. 2007
    ..Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment...
  19. ncbi request reprint Influence of hepatitis B virus genotypes on the response to antiviral therapies
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, 105 0001, Japan
    J Antimicrob Chemother 55:139-42. 2005
    ..Influence of genotypes on therapeutic response needs to be examined in patients infected with the other genotypes, particularly in those with genotype A or D infection...
  20. ncbi request reprint Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:491-8. 2005
    ..None developed cirrhosis or hepatocellular carcinoma (HCC) during follow-up. Our results suggest that long-term lamivudine therapy improves long-term prognosis, especially when additional treatment for breakthrough hepatitis is used...
  21. ncbi request reprint Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:83-90. 2006
    ....
  22. doi request reprint Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 52:301-9. 2009
    ....
  23. doi request reprint Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
    ..The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis...
  24. ncbi request reprint Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:91-7. 2003
    ..Comparison of long-term prognosis in patients with chronic hepatitis B treated with lamivudine, with or without severe acute exacerbation (SAE)...
  25. ncbi request reprint Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 69:376-83. 2003
    ..Our results suggest that substitution patterns in NS5A in patients with low titer of HCV genotype 2a may affect their response to IFN, but the response to therapy may be affected by mechanisms other than substitutions in this region...
  26. ncbi request reprint The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:315-21. 2003
    ..Genotype-dependent development of lamivudine resistance in hepatitis B virus (HBV) has not been reported...
  27. doi request reprint Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 83:1016-22. 2011
    ..This study emphasizes the importance of detection of aa substitutions in the core region before antiviral therapy...
  28. doi request reprint Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ....
  29. doi request reprint Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:575-82. 2010
    ....
  30. ncbi request reprint Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 Allele
    N Akuta
    Division of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, 105 0001, Japan
    J Med Virol 64:109-16. 2001
    ..05). Our findings suggest that a positive family history of liver disease and TAP2*0201 polymorphism may be risk factors for HCV-related liver cirrhosis in young adults...
  31. ncbi request reprint Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy
    Norio Akuta
    Department of Gastroenterology and Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan
    J Med Virol 71:504-10. 2003
    ..Large-scale studies of each mutant type should be conducted in the future to confirm these findings...
  32. doi request reprint Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1363-9. 2008
    ....
  33. ncbi request reprint Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 37:831-6. 2002
    ..The mechanism of variable response to interferon (IFN) monotherapy in patients infected with HCV genotype 2a is still unclear. Here we investigated the response in a large group of patients infected with genotype 2a...
  34. doi request reprint Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study
    K Ikeda
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Viral Hepat 16:437-43. 2009
    ..005) were independently associated with hepatocellular carcinogenesis. Existence of serum HBV DNA predicted a high hepatocellular carcinogenesis rate in a cohort of patients with non-B, non-C cirrhosis...
  35. ncbi request reprint Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen
    F Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 36:242-7. 2001
    ....
  36. ncbi request reprint Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis C
    M Kobayashi
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Intervirology 43:174-9. 2000
    ..The aim of this study was to assess the correlation between serial changes in serum alanine aminotransferase (ALT) levels and histological outcome 5 years after treatment of patients with chronic hepatitis C with interferon (IFN)...
  37. ncbi request reprint Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype
    K Chayama
    Department of Gastroenterology, Toranomon Hospital, Okinaka, Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-ku, 105, Tokyo, Japan
    J Virol Methods 95:33-45. 2001
    ..0 and bDNA ver 2.0 are superior in predicting the response in genotype 2a. The best cutoff value for predicting the response to IFN was different by genotype, which should be considered in selecting candidates for IFN treatment...
  38. ncbi request reprint Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection
    F Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Viral Hepat 11:271-6. 2004
    ..0075]. Our findings suggested that the SNP of the MxA gene is one of the important host factors that independently influences the response to IFN in patients with chronic HCV infection, especially those with a low viral load...
  39. ncbi request reprint Pathogenic significance and organic virus levels in patients infected with TT virus
    F Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 44:291-7. 2001
    ..Our results suggest that TTV may replicate in various tissues including the liver and may cause only mild liver damage...
  40. ncbi request reprint A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
    ....
  41. ncbi request reprint Wild-type precore and core promoter sequences in patients with acute self-limited or chronic hepatitis B
    M Kobayashi
    Research Institute for Hepatology, Dept of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 39:53-9. 2004
    ..Mutations in the precore region and core promoter were compared between patients with acute and chronic hepatitis B...
  42. ncbi request reprint Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:341-52. 2006
    ..More substitutions in the rt region and the other proteins may be related to the emergence of severe hepatitis caused by lamivudine-resistant virus...
  43. ncbi request reprint Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
    ..The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load...
  44. doi request reprint Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Hiromi Yatsuji
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 48:923-31. 2008
    ..We studied the long-term efficacy (median follow-up of 28 months) of adefovir (ADV) in combination with lamivudine (LAM) in 132 LAM-resistant Japanese patients with chronic genotype C-dominant hepatitis B virus (HBV) infection...
  45. doi request reprint Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:41-8. 2010
    ....
  46. ncbi request reprint Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
    Intervirology 50:16-23. 2007
    ..The purpose of this study was to elucidate the long-term outcome after interferon (IFN) therapy in chronic hepatitis C elderly patients...
  47. ncbi request reprint A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b
    Katsura Okamoto
    SRL Inc, Tokyo, Japan
    J Virol Methods 141:1-6. 2007
    ..The results suggest that the system described in this paper provides an effective, simple and low-cost approach to detection of nucleotide sequence variation in the core region of HCV-1b...
  48. ncbi request reprint Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:368-74. 2007
    ..The aim of this study was to investigate the factors associated with the response of lamivudine-resistant hepatitis B virus (HBV) during combination therapy with adefovir dipivoxil plus lamivudine...
  49. ncbi request reprint Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1286-92. 2007
    ..002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients...
  50. doi request reprint An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:43-8. 2009
    ..Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40-50% of patients infected with hepatitis C virus (HCV) of genotype 1 in high viral loads, which needs to be improved...
  51. doi request reprint Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
    ..The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C...
  52. doi request reprint Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
    ..73; 95% CI 1.77-4.20; P < 0.001), the patient had pre-diabetes (hazard ratio 2.19; 95% CI 1.43-3.37; P < 0.001), and age was >or=50 years (hazard ratio 2.10; 95% CI 1.38-3.18; P < 0.001)...
  53. ncbi request reprint Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
    ..026). The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR. The attainment of BR during IFN therapy is effective in reducing hepatocarcinogenesis for patients with chronic HCV infection...
  54. ncbi request reprint Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan
    Yoshiyuki Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 76:33-9. 2005
    ..Infection was cleared in only one of the six (17%) patients who received antiviral therapy...
  55. ncbi request reprint High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 39:155-61. 2004
    ....
  56. ncbi request reprint Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 75:27-34. 2005
    ..919. The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response, and might facilitate development of rational and effective therapeutic strategies...
  57. ncbi request reprint Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:182-9. 2003
    ..However, the patient cohorts in such studies are relatively small...
  58. ncbi request reprint Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 37:824-30. 2002
    ..The aim of this study was to determine the changes in these regions in patients with chronic hepatitis B virus (HBV) infection treated with lamivudine for 5 years...
  59. doi request reprint Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    J Gastroenterol Hepatol 24:429-35. 2009
    ..However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis...
  60. ncbi request reprint Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
    Fumitaka Suzuki
    Research Institute for Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 37:922-7. 2002
    ..We aimed to treat patients with chronic hepatitis B on long-term treatment with lamivudine who developed lamivudine-resistant hepatitis B virus (HBV) mutants along with clinical relapses...
  61. ncbi request reprint Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:969-74. 2004
    ..In Japan, there are few studies of long-term (more than 1 month) interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy and predictors of response to 6-month IFN therapy...
  62. ncbi request reprint Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1301-7. 2008
    ..The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection...
  63. ncbi request reprint Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:362-9. 2004
    ....
  64. ncbi request reprint Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Oncology 65:204-10. 2003
    ..Although hepatocellular carcinoma does develop after sustained response to interferon (IFN) in patients with chronic hepatitis C, details on the clinical prognosis have not been elucidated yet...
  65. ncbi request reprint Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 45:33-42. 2002
    ....
  66. ncbi request reprint Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 48:1654-7. 2003
  67. doi request reprint Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 25:892-8. 2010
    ..To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day...
  68. ncbi request reprint HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 70:355-60. 2003
    ..Our data suggested that during lamivudine therapy, core promoter and precore mutations do not influence HBeAg loss or seroconversion but may reduce the viral level upon HBeAg loss or seroconversion...
  69. ncbi request reprint [Corticosteroid withdrawal therapy in patients with chronic hepatitis B virus infection]
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital
    Nihon Rinsho 62:345-8. 2004
  70. ncbi request reprint Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
    Satoshi Mamori
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470 Tokyo, Japan
    J Gastroenterol 39:776-82. 2004
    ....
  71. doi request reprint Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
    ..This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic, interferon-treated patients with hepatitis C virus infection...
  72. doi request reprint Necessities of interferon therapy in elderly patients with chronic hepatitis C
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 122:479-86. 2009
    ..The significance of antiviral therapy for elderly patients with chronic hepatitis C virus (HCV) infection has not been elucidated...
  73. ncbi request reprint Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and the Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 45:71-8. 2002
    ..The influence of hepatitis C virus (HCV) subtypes on hepatocellular carcinogenesis was prospectively investigated...
  74. doi request reprint Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment
    Suguru Ogura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:179-88. 2009
    ..The aim of this study was to evaluate the impact of core aa substitutions on mortality in elderly patients...
  75. ncbi request reprint Hepatitis B virus-related hepatocellular carcinogenesis and its prevention
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 48:29-38. 2005
    ..026). A significant decrease or loss of serum HBV-DNA stops HCC development, and its sequential analysis could be very useful both in the prediction and early detection of small HCC...
  76. doi request reprint Clinical and virological effects of long-term (over 5 years) lamivudine therapy
    Yoshimasa Hashimoto
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 82:684-91. 2010
    ..Moreover, after the emergence of YMDD mutants, short latency to the emergence of YMDD mutant, mixed type mutants, and low baseline ALT level were associated with elevation of ALT or viral load...
  77. ncbi request reprint Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:174-82. 2005
    ..Comparison of virological and biochemical relapse in patients with chronic hepatitis B, based on continuation or discontinuation of lamivudine monotherapy...
  78. doi request reprint Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan akuta gi umin ac jp
    Intervirology 53:188-92. 2010
    ..In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2...
  79. ncbi request reprint Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection
    Kiminori Uka
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Gastroenterol 41:470-5. 2006
    ..The aim of this study was to analyze the response to interferon (IFN) monotherapy in young HCV patients...
  80. ncbi request reprint Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    Intervirology 49:82-90. 2006
    ..The anticarcinogenic capacity of interferon (IFN) was assessed in a cohort of Japanese patients with chronic hepatitis C en masse...
  81. ncbi request reprint The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1085-90. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for type C cirrhotic patients with genotype 2a and low virus load...
  82. ncbi request reprint Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1637-43. 2008
    ..The aim of the present study was to determine the rate of hepatocarcinogenesis and the risk factor in sustained virological responders...
  83. doi request reprint The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:265-9. 2008
    ..The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load...
  84. doi request reprint Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
    ..Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully...
  85. ncbi request reprint Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection
    Tomokazu Kawaoka
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:395-401. 2007
    ..The aim of this study was to evaluate the efficacy of lamivudine therapy in elderly patients with chronic HBV infection...
  86. ncbi request reprint Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:60-7. 2006
    ..In conclusion, patients persistently infected with HBV genotype A fare better than those with genotype B or C. However, high levels of HBV DNA continue in those in whom HBeAg persists along with fibrosis in the liver...
  87. ncbi request reprint Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 38:493-500. 2003
    ..if IFN is expected to be efficacious on the basis of genotype of HCV-RNA level; even if there is acute exacerbation of type-C chronic hepatitis, IFN should be re-administered in the HCV-RNA level has dropped subsequently...
  88. ncbi request reprint Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:459-65. 2006
    ....
  89. ncbi request reprint Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1155-60. 2007
    ..The aim of this study was to evaluate whether or not combination therapy of pegylated interferon (IFN) and ribavirin for chronic hepatitis (CH) C patients enhances the serum level of KL-6, a sensitive marker for interstitial pneumonia...
  90. ncbi request reprint Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 47:405-14. 2002
    ..We conclude that CSWT alone is a very short-term treatment of just three weeks that may be more effective for long-term clinical remission than CSWT followed by IFN-alpha in Japanese genotype C-dominant hepatitis B patients...
  91. ncbi request reprint Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:977-85. 2006
    ..To elucidate the incidence of hepatitis activation and hepatocellular carcinogenesis in patients with negative HBe antigen and normal aminotransferase, long-term observation was performed in a retrospective cohort...
  92. ncbi request reprint Prolonged hepatitis after acute infection with genotype H hepatitis B virus
    Norio Chihara
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1847-51. 2007
    ..Genotype H, the newest type of hepatitis B, could be the type which shows a poor response to lamivudine. The present paper is the first report, describing the clinical course of acute hepatitis B with genotype H from onset to remission...
  93. ncbi request reprint YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine
    Marie Matsuda
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 74:361-6. 2004
    ....
  94. ncbi request reprint Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 73:7-12. 2004
    ..The present study provides important information for the development of more effective and rational long-term lamivudine therapy for HBeAg-positive chronic hepatitis B patients infected exclusively with genotype..
  95. ncbi request reprint Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
    ..The purpose of the present paper was to identify factors that could influence the rapid progression of liver disease to hepatic failure, and assess the effects of lamivudine on serious disease...
  96. ncbi request reprint The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:355-60. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for chronic hepatitis C patients with low virus load...
  97. ncbi request reprint Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:355-61. 2004
    ....
  98. ncbi request reprint Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 38:158-63. 2003
    ..We therefore assessed the efficacy of prolonged IFN therapy in patients with HCV-genotype 1b and a high virus load...
  99. doi request reprint Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:390-5. 2010
    ..J. Med. Virol. 82:390-395, 2010. (c) 2010 Wiley-Liss, Inc...
  100. ncbi request reprint Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis
    Takashi Someya
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 41:1206-13. 2006
    ..Hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV) often recurs after surgical or medical treatment...
  101. ncbi request reprint Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:19-25. 2004
    ..We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not...